Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Anlotinib in Non-G12C KRAS-Mutant NSCLC
NCT04967079Phase 1Completed
- Sponsor
- Shanghai Chest Hospital
- Start
- Aug 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trametinib and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Started Aug 2021; status: completed.
02
Drugs
trametinibanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04967079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04967079.